{"id":9354,"date":"2020-05-14T18:37:51","date_gmt":"2020-05-14T13:07:51","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9354"},"modified":"2024-09-17T16:23:08","modified_gmt":"2024-09-17T10:53:08","slug":"recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi","title":{"rendered":"Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ&#8217;s anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a082e2db5806\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a082e2db5806\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi\/#Merck_supports_Peloton_Therapeutics_with_positive_kidney_cancer_data\" >Merck supports Peloton Therapeutics with positive kidney cancer data<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi\/#Thermo_Fisher_WuXi_and_Mayo_Clinic_to_develop_COVID-19_antibody_test\" >Thermo Fisher, WuXi and Mayo Clinic to develop COVID-19 antibody test<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi\/#Johnson_Johnsons_anti-BCMA_CAR-T_sweeps_multiple_myeloma_aside\" >Johnson &amp; Johnson&#8217;s anti-BCMA CAR-T sweeps multiple myeloma aside<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi\/#Tafinlar-Mekinist_combo_of_Novartis_receives_a_boost\" >Tafinlar-Mekinist combo of Novartis receives a boost<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-merck-supports-peloton-therapeutics-with-positive-kidney-cancer-data\"><span class=\"ez-toc-section\" id=\"Merck_supports_Peloton_Therapeutics_with_positive_kidney_cancer_data\"><\/span><strong>Merck supports Peloton Therapeutics with positive kidney cancer data<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Merck is revealing the data from a phase 2 study of a HIF-2\u03b1 inhibitor after a year betting USD 1.05 billion on Peloton Therapeutics, and the deal is promising.&nbsp;<\/p>\n\n\n\n<p>The drug limited tumour growth in 43% and shrank tumors in 28% of patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/advanced-renal-cell-carcinoma-rcc-market\">kidney cancer<\/a> linked to a specific genetic condition, giving hope to a patient group that must undergo multiple abdominal surgeries, and to kidney cancer patients more broadly as well.<\/p>\n\n\n\n<p>Although the 28% response rate might seem less, Merck hopes to see the drug\u2014MK-6482\u2014work in more patients. Some of the trial patients have been taking the drug for 18 weeks or so, but others are ahead in their treatment.&nbsp;<\/p>\n\n\n\n<p>MK-6482 inhibits HIF-2\u03b1 (hypoxia-inducible factor-2 alpha), a protein that plays a role in maintaining tissue oxygen levels. Merck examined it in 61 patients with clear cell kidney cancer linked to von Hippel-Lindau (VHL) disease, a genetic condition that causes tumors and cysts to grow throughout the body.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-thermo-fisher-wuxi-and-mayo-clinic-to-develop-covid-19-antibody-test\"><span class=\"ez-toc-section\" id=\"Thermo_Fisher_WuXi_and_Mayo_Clinic_to_develop_COVID-19_antibody_test\"><\/span><strong>Thermo Fisher, WuXi and Mayo Clinic to develop COVID-19 antibody test<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Thermo Fisher Scientific is developing its <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\">COVID-19<\/a> antibody test through an ongoing, three-way partnership with WuXi Diagnostics and the Mayo Clinic, and slates to search for international authorizations for the test over the upcoming weeks.<\/p>\n\n\n\n<p>The ELISA test will be available to identify both IgM and IgG antibodies to the novel <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\">coronavirus <\/a>and is designed to run on an open instrument platform following a clinical evaluation at the Mayo Clinic.<\/p>\n\n\n\n<p>Since the outbreak was first identified, the scientific, regulatory and commercial teams were mobilized for virus analysis, identification, deployment of personal protective equipment as well as the development of therapies and vaccines.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Preventing the <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\">COVID-19<\/a> spread, it requires comprehensive testing solutions, and Thermo Fisher has joined hands with WuXi Diagnostics and Mayo Clinic to respond to the widespread need for antibody-based tests.\u00a0<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-johnson-johnson-s-anti-bcma-car-t-sweeps-multiple-myeloma-aside\"><span class=\"ez-toc-section\" id=\"Johnson_Johnsons_anti-BCMA_CAR-T_sweeps_multiple_myeloma_aside\"><\/span><strong>Johnson &amp; Johnson&#8217;s anti-BCMA CAR-T sweeps multiple myeloma aside<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Johnson &amp; Johnson&#8217;s BCMA-targeting <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market\">CAR-T<\/a> therapy cast out tumors in 86% of patients with advanced <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-multiple-myeloma-market\">multiple myeloma<\/a> in a phase 1b study. The treatment could benefit patients who face a dismal prognosis and usually live for just a few months with the standard of care.&nbsp;<\/p>\n\n\n\n<p>JNJ-4528 has kept <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market\">cancer <\/a>away for nine months in 86% of the patients, which is very different to what these patients would typically face. The treatment also shrivelled tumors in all 29 study patients.<\/p>\n\n\n\n<p>The study evaluated JNJ-4528 in <a href=\"https:\/\/www.delveinsight.com\/report-store\/bladder-cancer-market\">cancer <\/a>patients, whom it had returned after a median of five other treatments or had not reacted to the treatment in the first place. The majority of them (86%) had tried three different types of treatment: a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 antibody.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-tafinlar-mekinist-combo-of-novartis-receives-a-boost\"><span class=\"ez-toc-section\" id=\"Tafinlar-Mekinist_combo_of_Novartis_receives_a_boost\"><\/span><strong>Tafinlar-Mekinist combo of Novartis receives a boost<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The checkpoint inhibitors and targeted therapies have transformed <a href=\"https:\/\/www.delveinsight.com\/report-store\/melanoma-market\">melanoma <\/a>treatment, but Novartis contemplates combining the two for working even better.&nbsp; &nbsp;&nbsp;<\/p>\n\n\n\n<p>Moreover, it has some new data to bolster its case. The duo Tafinlar and Mekinist with experimental PD-1-blocking spartalizumab cast out tumors in 44% of patients with advanced <a href=\"https:\/\/www.delveinsight.com\/report-store\/melanoma-epidemiology-forecast\">melanoma<\/a>, as shown in phase 3 data.<\/p>\n\n\n\n<p>The study examined the trio as first-line therapy in 36 patients with stage 4 <a href=\"https:\/\/www.delveinsight.com\/report-store\/melanoma-pipeline-insight\">melanoma <\/a>that had spread to different parts of the body. The patients had a specific <a href=\"https:\/\/www.delveinsight.com\/report-store\/braf-mutant-metastatic-melanoma-market\">BRAF mutation<\/a>: BRAF V600.<\/p>\n\n\n\n<p>Moreover, to eliminate tumors in 44% of those patients, the study saw that the treatment shrivelled tumors in 78% of patients. Tafinlar, a BRAF inhibitor, and Mekinist, a MEK inhibitor, are already approved to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/braf-mutant-metastatic-melanoma-epidemiology-forecast\">BRAF <\/a>V600-mutant melanoma, but the investigators informed that the impact of BRAF+MEK inhibition on the tumour microenvironment (TME) suggests combined targeted therapy and immunotherapy may enhance outcomes.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck supports Peloton Therapeutics with positive kidney cancer data Merck is revealing the data from a phase 2 study of a HIF-2\u03b1 inhibitor after a year betting USD 1.05 billion on Peloton Therapeutics, and the deal is promising.&nbsp; The drug limited tumour growth in 43% and shrank tumors in 28% of patients with kidney cancer [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9357,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18321,2734,349,18320,395,420,423,2584,639,902,18319],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-9354","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-advanced-multiple-myeloma","tag-johnson-and-johnson","tag-latest-pharma-news","tag-mayo-clinic","tag-merck","tag-news","tag-novartis","tag-peloton-therapeutics","tag-pharma-news","tag-thermo-fisher","tag-wuxi","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Merck, Thermo Fisher, WuXi<\/title>\n<meta name=\"description\" content=\"Johnson &amp; Johnson&#039;s BCMA-targeting CAR-T therapy cast out tumors in 86% of patients with advanced multiple myeloma in a phase 1b study.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Merck, Thermo Fisher, WuXi\" \/>\n<meta property=\"og:description\" content=\"Johnson &amp; Johnson&#039;s BCMA-targeting CAR-T therapy cast out tumors in 86% of patients with advanced multiple myeloma in a phase 1b study.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-14T13:07:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T10:53:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/14183546\/news-3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Merck, Thermo Fisher, WuXi","description":"Johnson & Johnson's BCMA-targeting CAR-T therapy cast out tumors in 86% of patients with advanced multiple myeloma in a phase 1b study.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Merck, Thermo Fisher, WuXi","og_description":"Johnson & Johnson's BCMA-targeting CAR-T therapy cast out tumors in 86% of patients with advanced multiple myeloma in a phase 1b study.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-05-14T13:07:51+00:00","article_modified_time":"2024-09-17T10:53:08+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/14183546\/news-3.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi","name":"Pharma News | Merck, Thermo Fisher, WuXi","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/14183546\/news-3.jpg","datePublished":"2020-05-14T13:07:51+00:00","dateModified":"2024-09-17T10:53:08+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Johnson & Johnson's BCMA-targeting CAR-T therapy cast out tumors in 86% of patients with advanced multiple myeloma in a phase 1b study.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/14183546\/news-3.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/14183546\/news-3.jpg","width":772,"height":482,"caption":"pharma-news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/14183546\/news-3-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Advanced Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Johnson and Johnson<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Mayo Clinic<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Peloton therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Thermo Fisher<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">WuXi<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Advanced Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">Johnson and Johnson<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Mayo Clinic<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Peloton therapeutics<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Thermo Fisher<\/span>","<span class=\"advgb-post-tax-term\">WuXi<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on May 14, 2020","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on May 14, 2020 6:37 pm","modified":"Updated on Sep 17, 2024 4:23 pm"},"featured_img_caption":"pharma-news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9354"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9354\/revisions"}],"predecessor-version":[{"id":29558,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9354\/revisions\/29558"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9357"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9354"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9354"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}